Value Creation

A Proven Track Record of Value Creation

Since our founding in 2002, we have delivered results for partners of all sizes, across all major therapeutic areas, helping partners achieve more than $2.5 billion in deal value. 

Learn more about our track record of value creation through some of these success stories.

Value Created: Nitto entered into an exclusive worldwide licensing agreement with BMS which included a $100M upfront payment and subsequent development milestones and royalties.

Asset: Novel siRNA therapy in advanced non-alcoholic steatohepatitis (NASH) and cirrhosis due to NASH

Approach: A development partnership with Nitto to advance their lead asset through completion of Phase1b/2a clinical trials. The RRD product development team (PDT) worked closely with Nitto to define the development strategy and had direct responsibility for executing the regulatory and clinical operations plan including interactions with FDA and EMA.

Value Created: SmartCells was acquired by Merck & Co. in a deal valued at more than $500M.

Asset: Platform technology in endocrine disorders

Approach: A development partnership with SmartCells that began as the company was being formed as a spin-out from MIT. RRD worked closely with SmartCells on strategy and development planning for the lead asset and had an active role in securing initial and follow-on investments to advance the program through IND.

Value Created: Otsuka acquired ADHD drug from Neurovance for $250MM in upfront and near-term development milestones plus additional non-disclosed sales milestones.

Asset: Novel triple re-uptake inhibitor for patients with ADHD

Approach: Neurovance initiated a development partnership with RRD to prepare the company for End of Phase 2 Meeting (EOP2) with FDA and initiation of Phase 3 clinical studies. RRD provided senior development leadership for the program including serving as acting Chief Medical Officer for the company, and had an active role in supporting Neurovance’s exploration of strategic options and follow-on investment.

Value Created: ISIS Pharmaceuticals buy-back of equity at pre-negotiated price of $120M. Products were partnered with Genzyme and J&J which resulted in $500M+ in licensing fees. Genzyme and Isis announced FDA approval of KYNAMRO™ (mipomersen sodium) for treatment of homozygous familial hypercholesterolemia.

Assets: Cholesterol and diabetes compounds

Approach: DevCo created and managed by RRD, and funded by Symphony Capital with $75M. Three assets in-licensed from Isis Pharmaceuticals to advance through human proof-of-concept development.